Evidence mapPaperPMID 33773045Full record

ArticleJournal of thrombosis and haemostasis : JTH2021

Hemostatic factors, inflammatory markers, and risk of incident venous thromboembolism: The Multi-Ethnic Study of Atherosclerosis.

Line H Evensen, Aaron R Folsom, James S Pankow, John-Bjarne Hansen, Matthew A Allison, Mary Cushman, Pamela L Lutsey

Open access · bronzeAbstract read
In one paragraph

Article in Journal of thrombosis and haemostasis : JTH, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
2.8field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Line H EvensenK.G. Jebsen - Thrombosis Research and Expertise Center (TREC), Department of Clinical Medicine, UiT-The Arctic University of Norway, Tromsø, Norway.ORCID 0000-0002-7169-9408
Aaron R FolsomDivision of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, MN, USA.ORCID 0000-0003-2635-2699
James S PankowDivision of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, MN, USA.
John-Bjarne HansenK.G. Jebsen - Thrombosis Research and Expertise Center (TREC), Department of Clinical Medicine, UiT-The Arctic University of Norway, Tromsø, Norway.
Matthew A AllisonDepartment of Family Medicine and Public Health, University of California, San Diego, CA, USA.
Mary CushmanDepartment of Medicine, Larner College of Medicine, University of Vermont, Burlington, VT, USA.ORCID 0000-0002-7871-6143
Pamela L LutseyDivision of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, MN, USA.ORCID 0000-0002-1572-1340
University of Minnesota · USUniversity Hospital of North Norway · NOUniversity of California San Diego · USUniversity of Vermont · US

Funding

TOXICOLOGYP30ES000002 · NIEHS · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI Marc G Weisskopf · 1985 to 2023
$12.4M
MULTI-ETHNIC STUDY OF ATHEROSCLEROSIS (MESA), COORDINATING CENTER - TASK AREA A - CORE STUDY OPERATIONS75N92020D00001 · UNIVERSITY OF WASHINGTON · 2025 to 2025
$972k
SUBCLINICAL CARDIOVASCULAR DISEASE STUDYN01HC095166 · UNIVERSITY OF VERMONT &ST AGRIC COLLEGE · 1999 to 2001
$758k
SUBCLINICAL CARDIOVASCULAR DISEASE STUDY-FIELD CENTERN01HC095162 · JOHNS HOPKINS UNIVERSITY · 1999 to 2000
$694k
SUBCLINICAL CARDIOVASCULAR DISEASE STUDY--FIELD CENTERN01HC095161 · COLUMBIA UNIVERSITY HEALTH SCIENCES · 1999 to 2001
$642k
SUBCLINICAL CARDIOVASCULAR DISEASE STUDY--FIELD CENTERN01HC095165 · WAKE FOREST UNIVERSITY · 1999 to 2001
$616k
SUBCLINICAL CARDIOVASCULAR DISEASE STUDY--FIELD CENTERN01HC095160 · UNIVERSITY OF CALIFORNIA LOS ANGELES · 1999 to 2001
$592k
SUBCLINICAL CARDIOVASCULAR DISEASE STUDY-FIELD CENTERN01HC095164 · NORTHWESTERN UNIVERSITY · 1999 to 2001
$511k
SUBCLINICAL CARDIOVASCULAR DISEASE STUDY--FIELD CENTERN01HC095163 · UNIVERSITY OF MINNESOTA TWIN CITIES · 1999 to 2001
$443k
SUBCLINICAL CARDIOVASCULAR DISEASE STUDYN01HC095168 · JOHNS HOPKINS UNIVERSITY · 1999 to 2000
$375k
SUBCLINICAL CARDIOVASCULAR DISEASE COORDINATING CENTER-N01HC95159-268095159N01HC095159 · UNIVERSITY OF WASHINGTON · 1999 to 2005
$304k
MULTI-ETHNIC STUDY OF ATHEROSCLEROSIS (MESA), FIELD CENTER (FC): TASK AREA A - CORE OPERATIONS75N92020D00005 · UNIVERSITY OF CALIFORNIA LOS ANGELES · 2025 to 2025
$282k
National Center for Advancing Translational Sciences (NCATS) UL1-TR-000040National Center for Advancing Translational Sciences (NCATS) UL1-TR-001079National Center for Advancing Translational Sciences (NCATS) UL1-TR-001420NCATS NIH HHS UL1 TR000040NCATS NIH HHS UL1 TR001079NCATS NIH HHS UL1 TR001420NHLBI NIH HHS 75N92020D00001NHLBI NIH HHS 75N92020D00002NHLBI NIH HHS 75N92020D00003NHLBI NIH HHS 75N92020D00004NHLBI NIH HHS 75N92020D00005NHLBI NIH HHS 75N92020D00006NHLBI NIH HHS 75N92020D00007NHLBI NIH HHS HHSN268201500003CNHLBI NIH HHS HHSN268201500003INHLBI NIH HHS N01 HC095159NHLBI NIH HHS N01 HC095160NHLBI NIH HHS N01 HC095161NHLBI NIH HHS N01 HC095162NHLBI NIH HHS N01 HC095163NHLBI NIH HHS N01 HC095164NHLBI NIH HHS N01 HC095165NHLBI NIH HHS N01 HC095166NHLBI NIH HHS N01 HC095167NHLBI NIH HHS N01 HC095168NHLBI NIH HHS N01 HC095169NHLBI NIH HHS N01-HC-95159NHLBI NIH HHS N01-HC-95160NHLBI NIH HHS N01-HC-95161NHLBI NIH HHS N01-HC-95162NHLBI NIH HHS N01-HC-95163NHLBI NIH HHS N01-HC-95164NHLBI NIH HHS N01-HC-95165NHLBI NIH HHS N01-HC-95166NHLBI NIH HHS N01-HC-95167NHLBI NIH HHS N01-HC-95168NHLBI NIH HHS N01-HC-95169
6 · The paper itself

Abstract

backgroundSeveral hemostatic factors and inflammatory markers are associated with the risk of incident venous thromboembolism (VTE), however, most existing data are from case-control studies in Caucasian populations.

objectivesWe aimed to prospectively confirm previous findings and explore less studied biomarkers in relation to VTE risk in a multi-racial/multi-ethnic cohort.

methodsCirculating levels of factor VIII, fibrinogen, D-dimer, plasmin-antiplasmin complex (PAP), C-reactive protein (CRP), and interleukin-6 (IL-6) were measured at baseline (2000-2002) in 6706 participants of the Multi-Ethnic Study of Atherosclerosis. Incident VTE was identified using hospitalization discharge codes from baseline to December 31, 2015. Hazard ratios (HRs) of VTE were estimated in Cox regression models.

resultsThere were 227 events during a median of 14 years of follow-up. Compared with participants in the lowest quartile, the HRs for those above the 95th percentile and p for trend across categories were 3.50 (95% confidence interval [CI] 1.98-6.19; p < .001) for D-dimer, 1.49 (95% CI 0.84-2.63; p = .02) for factor VIII, 1.32 (95% CI 0.76-2.28; p = .99) for fibrinogen, 1.92 (95% CI 1.08-3.42; p = .15) for PAP, 1.68 (95% CI 0.81-3.48; p = .08) for CRP, and 2.55 (95% CI 1.15-5.66; p = .07) for IL-6, after adjustment for demographics and body mass index. For CRP and IL-6, follow-up was restricted to 10 years because of violations of the proportional hazards assumption. No significant interactions by age/ethnicity were observed.

conclusionsWe demonstrated a fairly novel association between PAP and risk of incident VTE, and contributed further prospective confirmation regarding the associations of D-dimer, factor VIII, and IL-6 with VTE.

Indexed as

AtherosclerosisHemostaticsVenous ThromboembolismBiomarkersEthnicityFibrinogenHumansProspective StudiesRisk FactorsBiomarkersFibrinogenHemostaticsblood coagulationfibrinolysisinflammationrisk factorsvenous thromboembolism

Identifiers

PMID33773045
PMCPMC8606033
OpenAlexW3152125273

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.